Drug · SGLT2 inhibitor · SGLT2 inhibitor · Sourced compound
Empagliflozin structure · mechanism
PubChem CID 11949646. Molecular formula C23H27ClO7. Independently assigned structure; reviewed 2026-10-08. Family grouping is editorial and does not establish shared activity.
Empagliflozin 2D structure
- Role
- Drug
- Family
- SGLT2 inhibitor series
- Mechanism class
- SGLT2 inhibitor
- InChIKey
OBWASQILIWPZMG-QZMOQZSNSA-N
- Structure checked
- 2026-10-08
- Molecular formula
- C23H27ClO7
- Structure source
- PubChem
- PubChem CID
- 11949646
- InChI Key
- OBWASQILIWPZMG-QZMOQZSNSA-N
- FDA / EMA
- FDA/EMA
- ClinicalTrials.gov
- empagliflozin heart failure
SMILES
C1COC[C@H]1OC2=CC=C(C=C2)CC3=C(C=CC(=C3)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)ClTags
Related compounds
External IDs · BioMoa
StructureMoa is a chemical-structure exploration tool. Structural similarity, clustering, and SAR relationships are intended for research exploration and do not establish shared potency, selectivity, safety, efficacy, or clinical performance.
Editorial responsibility and corrections
Operated and edited by the independent StructureMoa project. Explanations use AI assistance; structural identity and similarity are checked against source records and calculation tests. Molecular data and clinical or regulatory evidence have separate review scopes.
- Source structures
- PubChem · CID / SMILES / InChIKey
- Calculations and automated checks
- RDKit · Morgan / SMARTS
- Disclosed specialist review
- No separate external specialist review is disclosed. Passing automated tests is not specialist review of clinical claims.
For a correction, include the page URL, molecule name or CID, the field in question and a supporting source. Corrections are checked against sources, and the affected editorial update date is changed when a correction is published. [email protected]